CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Ibrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02736617
NCT02736617Phase 2Completed
CompareCT.gov

A Phase II Study of Obinutuzumab (GA-101) in Combination With Ibrutinib (I) for the Treatment of Relapsed Mantle Cell Lymphoma

OHSU Knight Cancer Institute·interventional·Posted Apr 13, 2016·Updated Jan 5, 2022

In Brief

A Phase 2 clinical trial evaluating Ibrutinib and Obinutuzumab for Recurrent Mantle Cell Lymphoma and Refractory Mantle Cell Lymphoma. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This phase II trial studies how well obinutuzumab works in combination with ibrutinib in treating patients with mantle cell lymphoma that has returned (relapsed) or that does not respond to treatment (refractory). Obinutuzumab binds to a protein called cluster of differentiation (CD)20, which is found on B cells and some types of leukemia and lymphoma cells and help the immune system kill cancer cells. Ibrutinib blocks a protein called Bruton's tyrosine kinase (BTK), which may help keep cancer cells from growing. Giving obinutuzumab in combination with ibrutinib may kill more cancer cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
CountriesUnited States
CollaboratorsGenentech, Inc., Oregon Health and Science University

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 13, 2016
Enrollment StartJul 5, 2016
Primary CompletionJun 2, 2021
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 10.2 years ago

Interventions

Ibrutinibdrug

Given PO

Obinutuzumabbiological

Given IV